NewsRx

Search our medical news database

Cardiology

Acadesine reduces 2-year mortality following heart attacks in heart bypass patients

Published in Drug Week, June 16th, 2006

PeriCor Therapeutics, Inc., announced that a landmark study of its novel cardioprotective agent, acadesine, demonstrated the drug's ability to prolong long-term survival in those patients who suffer heart attacks following heart bypass surgery.

Among patients undergoing coronary artery bypass graft (CABG) surgery who suffered post-reperfusion myocardial infarction (MI), mortality after 2 years was reduced by 77% with acadesine treatment.

This study, entitled "Post-Reperfusion Myocardial Infarction: Long-Term Survival Improvement Using Adenosine Regulation with Acadesine," was published online by the Journal of the American College of...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook